The MHRA has issued specific safety guidance on both medicines, and if the combination is clinically unavoidable, a baseline ECG and electrolyte check should be discussed with a prescribing clinician
No.BCP32133 No.307986-98-7 Product Details Cat
The diabetes and obesity markets are massive, but are also intensely competitive and rapidly evolving
Advanced dual GLP-1/GIP receptor agonist for appetite signaling & metabolic pathway research
The medication requires gradual dose titration over several months to minimize gastrointestinal side effects, which are the most common tolerability concerns
Then a major breakthrough occurred with the discovery of a peptide similar in structure and function to GLP-1, exendin-4 (Ex4), that is resistant to degradation by DPP-4 (Thorens et al., 1993